New client will use Dario's integrated approach to support
long-term behavior change for employees living with diabetes,
pre-diabetes, hypertension and those taking a GLP-1
medication
NEW
YORK, Dec. 5, 2023 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital health market, announced today a new contract to
provide cardiometabolic and GLP-1 solutions to a national employer
(the "Employer") beginning in January
2024.
The Employer, a national logistics company, selected Dario
to deliver integrated support for employees living with diabetes,
pre-diabetes, weight management and hypertension, while also
providing a tailored experience for employees taking a GLP-1
medication. Dario combines intelligent technologies and expert
human support with billions of data insights gathered from a decade
of consumer engagement to deliver highly personalized experiences
that keep people engaged over time for optimal results.
"GLP-1 medications are creating tremendous upheaval for
employers and payers, and our new contract with the Employer is a
great example of how Dario is helping employers address the growing
and costly problem. Dario's solutions have been proven, in prior
studies, to deliver long-term behavior change with and without a
GLP-1 medication to help employers like the Employer realize the
full potential in health outcomes," said Rick Anderson, President of Dario.
About Dario's GLP-1 solution
Dario's GLP-1 solution delivers the U.S. Food and Drug
Administration (FDA) required behavior change support component to
members enrolled in the cardiometabolic solution before or during
use of a GLP-1. Members using a GLP-1 or other anti-obesity
medication receive a highly personalized experience optimizing
digital coaching and professional human support, including guidance
from a Certified Diabetes Educator, to improve overall health.
As part of their experience, members have access to Dario's
Medication Cabinet, a digital tool to help members track medication
adherence, along with tailored lifestyle change programs and tools
to support sustainable behavior change.
Data insights available as part of Dario's solution help
partners better understand member adherence and the impact on
overall member health.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it
discusses the expected timing of the launch of the Employer
solution and the benefits that may be realized by members using
Dario's solutions. Without limiting the generality of the
foregoing, words such as "plan," "project," "potential," "seek,"
"may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. Readers are cautioned that certain
important factors may affect the Company's actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release. Factors that may
affect the Company's results include, but are not limited to,
regulatory approvals, product demand, market acceptance, impact of
competitive products and prices, product development,
commercialization or technological difficulties, the success or
failure of negotiations and trade, legal, social and economic
risks, and the risks associated with the adequacy of existing cash
resources. Additional factors that could cause or contribute to
differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parella
Investor Relations Manager
+315-378-6922
Media Contact
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo -
https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/national-employer-selects-dario-cardiometabolic-and-glp-1-solutions-to-improve-employee-health-302005689.html
SOURCE DarioHealth Corp.
